Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jodie Morrison | F | 48 |
Tokai Pharmaceuticals, Inc.
 Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 11 years |
| John S. McBride | M | 72 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 3 years |
| Stephen Buckley | M | 74 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | - |
| Reinhard Ambros | M | 67 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 5 years |
| Susan Stewart | F | 64 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 6 years |
| Jessica Fees | F | 52 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 6 years |
| Martin D. Williams | M | 58 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 2 years |
| Campbell Murray | M | 48 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 5 years |
| Cheryl L. Cohen | F | 58 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 5 years |
| Timothy Barberich | M | 76 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 8 years |
| Joseph C. Noviello | M | - |
State University of New York College at Oswego
| 4 years |
| Frank T. Caprio | M | - |
Suffolk University
| 3 years |
| Tom Bardenett | M | 60 |
State University of New York College at Oswego
| 4 years |
| Rob Roy | M | - |
Suffolk University
| 3 years |
| John D. Colucci | M | - |
Suffolk University
| 3 years |
| David S. Casebier | M | - |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 3 years |
| Charles Aggouras | M | 57 |
Suffolk University
| 4 years |
| Brett Chandler | M | - |
Suffolk University
| - |
| Mark Marano | M | - |
State University of New York College at Oswego
| 4 years |
| David Wang | M | - |
Suffolk University
| 2 years |
| James M. McKenna | M | - |
Suffolk University
| 3 years |
| Theresa Hoyt | F | - |
Suffolk University
| 4 years |
| Brian Emanuelson | M | - |
Suffolk University
| 5 years |
| Teri D. Vries | F | - |
State University of New York College at Oswego
| 4 years |
| Adrian M. Senderowicz | M | 60 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 1 years |
| Wing Kin Chow | M | 57 |
Suffolk University
| 4 years |
| Daniel Cannistra | M | - |
State University of New York College at Oswego
| 4 years |
| Karen Ferrante | M | 66 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 2 years |
| Allan Shaw | M | 59 |
State University of New York College at Oswego
| 4 years |
| Nique Fajors | M | - |
Suffolk University
| 4 years |
| Luis Manuel Raposo | M | - |
Suffolk University
| 1 years |
| Daniel Francis Raite | M | - |
State University of New York College at Oswego
| 4 years |
| Joseph Liberatore | M | 61 |
State University of New York College at Oswego
| 4 years |
| Scott C. Chappel | M | 73 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 6 years |
| Kenneth John Kirsch | M | 63 |
State University of New York College at Oswego
| 4 years |
| William J. Begley | M | 69 |
Suffolk University
| 2 years |
| John Gerald Fitzgerald | M | 60 |
Suffolk University
| 2 years |
| Joseph P. Cerqua | M | - |
State University of New York College at Oswego
| 4 years |
| Kevin Michael Klingert | M | 61 |
State University of New York College at Oswego
| 4 years |
| Jeffrey George Kanter | M | - |
State University of New York College at Oswego
| 4 years |
| Paul M. Drury | M | - |
Suffolk University
| 4 years |
| John J. Concannon | M | - |
Suffolk University
| 3 years |
| James Triandiflou | M | 59 |
State University of New York College at Oswego
| 4 years |
| Glenn Myers | M | - |
State University of New York College at Oswego
| 4 years |
| Celia H. Leber | F | - |
Suffolk University
| 3 years |
| Thomas Francis Gibson | M | - |
Suffolk University
| 2 years |
| Dennis Fernandez | M | - |
Suffolk University
| 4 years |
| Gerald Quirk | M | 56 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 1 years |
| Dave W. Kantaros | M | - |
Suffolk University
| 3 years |
| Lee Kalowski | M | 43 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 2 years |
| Nader F. Darehshori | M | 87 |
Suffolk University
| 3 years |
| Edmund J. Cienava | M | - |
Suffolk University
| 4 years |
| Jim Coughlin | M | - |
Suffolk University
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 53 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Cindy Driscoll
- Personal Network